Stiris Research Inc. Phase I Study in COVID-19
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, announced today that it had been awarded a Phase 1, Double Blind, Randomized, Placebo Controlled COVID-19 treatment study.
“Stiris has been discussing internally our interest in working with companies that have treatment options for COVID-19, as we understand that to move through the pandemic, we will need both preventative vaccine and disease treatments in order to combat the SARS-CoV-2 virus and its variants,” said Amanda Carrera, Vice President, Stiris Research Inc.
SARS-CoV-2 is the coronavirus that is responsible for COVID-19, the respiratory illness responsible for the ongoing pandemic. This is a virus of the species severe acute respiratory syndrome-related coronavirus (SARSr-CoV). The virus primarily spreads through close contact and respiratory droplets (aerosols) that are exhaled when talking, breathing, as well as from coughs and sneezes. It largely enters the human cells by binding to angiotensin converting enzyme 2 (ACE2), a membrane protein that regulates the renin-angiotensin system (https://www.who.int/emergencies/diseases/novel-coronavirus-2019)
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: